



VettaFi Weight Loss Drug & Treatment Index

THINR

Table of Contents

Introduction	3
Index Objective	3
Highlights	3
Dates	3
Supporting Documents	3
Eligibility Criteria and Index Construction	4
Universe	4
Index Construction	4
Constituent Selection	4
Constituent Weightings & Constraints	5
Index Maintenance	5
Rebalancing and Reconstitution	5
Corporate Actions	5
Index Information	5
Index Calculation	6
Index Governance	6
Index Policies	6
Contact Information	6
Appendix	8

Introduction

Index Objective

The VettaFi Weight Loss Drug & Treatment Index is an index of global companies expected to economically benefit from weight loss drug development. The Index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who give access to Amylin agonists & analogs or GLP-1 agonists & analogs, including dual GLP-1 agonists & analogs.

Highlights

The Index includes companies that have launched production or are in FDA clinical trials.

Dates

Reference Dates: Last Business Date of month prior to Rebalance/Reconstitution Month.

Reconstitution Dates: Indexes reconstituted quarterly on the third Friday of the last month of each calendar quarter.

Weight Date: Thursday prior to second Friday of Rebalance/Reconstitution Month.

Rebalance Dates: Indexes are rebalanced quarterly on the third Friday of the last month of each calendar quarter.

Supporting Documents

This methodology is meant to be read in conjunction with supporting documents providing greater detail with respect to the policies, procedures and calculations described herein.

The list of the main supplemental documents for this methodology can be found in the Methodologies and Governance tabs on the [Index Resources](#) page as follows:

Supporting Documents
Index Maintenance Policy
Index Governance
Index Policies
Methodology Policies
Glossary
Index Change and Consultation Policy

Eligibility Criteria and Index Construction

Universe

Constituents of countries in the VettaFi Full World Index (see Appendix) deemed to have sufficient access, liquidity, and foreign exchange markets for the trading needs of funds that support foreign investors. China constituents are restricted to Hong Kong listing and Depositary Receipts. Indian shares are restricted to Depositary Receipts.

Index Construction

Constituent Selection

Twenty constituents are chosen from companies that are classified as a Weight Loss Drug Manufacturer, Combination Therapies Drug Manufacturer, or a Telehealth Provider based on the following criteria:

- Weight Loss Drug Manufacturers:

Companies with GLP-1 Agonist, Amylin Agonists & Analogs, or Dual Agonist drugs that are either launched or are in FDA clinical trials. These drug manufacturers are additionally classified into three subsegments depending on their phase of development: Commercial, Phase 3, and Phase 2 & below.

- Combination Therapies Drug Manufacturer:

Combination therapies drug manufacturers are those companies with drugs that are either being marketed or undergoing FDA clinical trials for combination use with Amylin agonists & analogs or GLP-1 agonists & analogs, including dual GLP-1 agonists & analogs.

- Telehealth Provider:

Companies providing telehealth solutions to facilitate access to Amylin agonists & analogs or GLP-1 agonists & analogs, including dual GLP-1 agonists & analogs.

Additionally, all companies must meet the following criteria:

- Minimum Company Market Cap – 500 million USD
- Minimum Average Daily Traded Value (ADTV) of 1 million USD

If more than 20 constituents meet the above criteria, companies are excluded in the following order until 20 constituents remain:

Companies with the lowest full market caps that are not part of the Commercial or Phase 3 subsegments of the Weight Loss Drug Manufacturers segment.

Companies with the lowest full market caps that are part of the Commercial or Phase 3 subsegments of the Weight Loss Drug Manufacturers segment.

Constituent Weightings & Constraints

Companies are float market cap weighted with the following caps and constraints:

- Weight Loss Drug Manufacturers with commercial drugs are capped at 15%.
- Weight Loss Drug Manufacturers with a drug in Phase 3 are capped at 8%.
- Weight Loss Drug Manufacturers with a drug in phase 2 or below, Combination Therapies Drug Manufacturer, and Telehealth Providers are capped at 5%.
- The sum of all constituent weights greater than 5% must be less than or equal to 45% of the total index.

Capped weights are redistributed proportionally.

Index Maintenance

Rebalancing and Reconstitution

The Indexes are rebalanced on the “Rebalance Date” and additionally reconstituted on the “Reconstitution Date”. Pricing used in share weights used for reconstitutions are as of the “Weight Date”. Share weights for the rebalanced Indexes are computed as of the “Weight Date”. Changes to the Indexes related to the rebalances are as of the “Rebalance Date”. Additions are only made on reconstitution dates.

Corporate Actions

Please refer to the Index Maintenance Policy document for information on Corporate Action processing.

Index Information

Index history availability, base dates and base values are shown in the table below.

Index	Price Index	Base Date	Base Value	Total Return Index	Base Date	Base Value
VettaFi Weight Loss Drug & Treatment Index	THINR	06/18/21	1000	THINRT	06/18/21	1000

Methodology Updates and Changes

Date	Version	Previous	New
Apr 2024	1.0.1	Name: VettaFi Weight Loss Drug Index	VettaFi Weight Loss Drug & Treatment Index
May 2024	1.0.2	Added clarification to Objective: Replaced: The VettaFi Weight Loss Drug Index is an index of global companies who are manufacturers in the GLP-1 pharmaceuticals business or who enable the business.	With: The VettaFi Weight Loss Drug & Treatment Index is an index of global companies expected to economically benefit from GLP-1 drug development, approval, or market adoption. This includes companies who are manufacturers in the GLP-1 pharmaceuticals business or are GLP-1 enablers

May 2024	1.0.2	Added Clarification to Enablers description: Replaced: Companies involved with the outsourced development and manufacturing of GLP-1 Agonist Drugs. This includes companies conducting measurement and analysis or other work that supports GLP-1 Agonist production and distribution.	With: • Companies involved with the outsourced development and manufacturing of GLP-1 agonist drugs, also known as contract development and manufacturing organizations (CDMOs). • Companies conducting measurement and analysis of GLP-1 agonist drugs. • Companies involved in the distribution or administration of GLP-1 agonist drugs including coordination of prescriptions and drug-delivery mechanisms such as injection pens.
Jun 2024	1.1.0	Constituents of the S-Network Developed World Equity 5000 Index (SNDW5K) or the VettaFi Developed World Index (VFDW).	Constituents of countries in the VettaFi Full World Index (see Appendix) deemed to have sufficient access, liquidity, and foreign exchange markets for the trading needs of funds that support foreign investors. China constituents are restricted to Hong Kong listing and Depositary Receipts. Indian shares are restricted to Depositary Receipts.
Jun 2024	1.1.0		Added 1 million USD 3-month ADTV liquidity requirement.
Jun 2025	2.0.0	Selection based on “Drug Manufacturers” and “Enablers” segments with weight allocations.	20 constituents selected based on classification as a Weight Loss Drug Manufacturer, Combination Therapies Drug Manufacturer, or a Telehealth Provider segment. Individual caps applied based on segment and sub-segment classification.

Index Calculation

Please refer to the Index Maintenance Policy document for information on index calculations.

Index Governance

The index is governed and managed by a VettaFi Index Committee for the purpose of meeting the goals of the index. For more information, please refer to the Index Governance document.

Index Policies

Please refer to the Index Policies document for information regarding Announcements, Holiday Schedules, Unexpected Exchange Closures, and Recalculation Policy.

Contact Information

For any questions regarding an index, please contact: index.production@vettafi.com

Appendix

VettaFi Full World Index Countries

Australia	France	Malaysia	South Africa
Austria	Germany	Mexico	South Korea
Belgium	Greece	Netherlands	Spain
Brazil	Hong Kong	New Zealand	Sweden
Canada	Hungary	Norway	Switzerland
Chile	India	Peru	Taiwan
China	Indonesia	Philippines	Thailand
Colombia	Ireland	Poland	Turkey
Czech Republic	Israel	Portugal	United Arab Emirates
Denmark	Italy	Qatar	United Kingdom
Egypt	Japan	Saudi Arabia	United States
Finland	Kuwait	Singapore	